![]() ![]() The gene encodes the calcium-activated cysteine protease. We identified CAPN5 as the first gene to cause uveitis. Genome-wide knockout screen of mouse eye phenotypes. Protein crystallography of Calpain-5 and its signaling mechanisms in the retina. The findings are then directly translated into personalized medical therapies in humans. These are validated using biochemistry, tissue culture, and animal models. We use high-throughput technologies (proteomics, genomics, phenomics) to identify candidate disease molecules. My laboratory team is composed of scientists, surgeons, engineers, and students who are dedicated to curing blindness. ![]() Our focus is the development of personalized medicine for eye diseases through translation of our discoveries in proteomics, genomics, and phenomics in humans, mice and tissue culture models. He next specialized in vitreoretinal diseases and surgery at the University of Iowa’s Retina Fellowship Program and joined as faculty in 2008. At UCLA he completed post doctoral laboratory research as an EyeSTAR Fellow. Upon completion, he joined the residency program at the Jules Stein Eye Institute at the University of California, Los Angeles. He then entered the Medical Scientist Training Program at the University of California, Irvine. ![]() Mahajan earned his bachelor’s degree in Molecular and Cell Biology at the University of California, Berkeley. He has published new surgical biomarker studies that are the first to use personalized proteomics to precisely diagnose and treat otherwise problematic retinal diseases. Mahajan is among only a handful of surgeons to perform human gene therapy for retinal disease. He has identified safer approaches for vitreoretinal surgery in children and adults, and provides second opinions for complex cases. He has developed enhanced surgeries for complex cases of retinal detachment, macular hole, macular edema, diabetes, macular degeneration, proliferative vitreoretinopathy, optic maculopathy, uveitis, and others. Mahajan has trained numerous surgical fellows that now operate around the world. Using translational proteomics, Mahajan’s multidisciplinary team is developing new precision health approaches using molecular biomarkers to diagnose retinal disease, select personalized therapies, and decode the anatomic structures of the human eye. They have also created in vivo models for diabetic retinopathy and uveitis. Mahajan and his team performed the first CRISPR gene editing therapy for eye disease in human stem cells. His research team discovered the first gene to cause non syndromic uveitis and is now using protein crystallography to design therapeutic inhibitors for calpain-5. He directs the NIH-funded Molecular Surgery and Omics Laboratory that uses high-throughput methods in genomics, proteomics, and phenomics to identify molecules involved in vitreoretinal disease. Mahajan is a Professor and vitreoretinal surgeon and scientist in the Department of Ophthalmology at Stanford University.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |